Lead Product(s) : Fluasterone
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : SteroTherapeutics will provide the study drug (non-androgenic analogue of dehydroepiandrosterone) and placebo to enable the NICHD to conduct the Phase 2 clinical trial in the treatment of the manifestations of Cushing syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
February 12, 2020
Lead Product(s) : Fluasterone
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement